Literature DB >> 26291283

Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.

DeRen Huang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26291283     DOI： 10.1212/WNL.0000000000001929

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  16 in total

Review 1.  Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Authors:  Jens Ingwersen; Orhan Aktas; Hans-Peter Hartung
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 3.  Sphingosine-1-phosphate receptors and innate immunity.

Authors:  Arielle M Bryan; Maurizio Del Poeta
Journal:  Cell Microbiol       Date:  2018-03-23       Impact factor: 3.715

4.  Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod.

Authors:  Chengde Pham; Iwan Bennett; Rondhir Jithoo
Journal:  BMJ Case Rep       Date:  2017-07-06

Review 5.  Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors:  S N Levin; T B Kaplan
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

6.  Cryptococcal Meningitis in a Fingolimod-Treated Patient: Positive Antigen Test a Year Before Onset.

Authors:  Reiji Aoki; Masahiro Mori; Yo-Ichi Suzuki; Akiyuki Uzawa; Hiroki Masuda; Tomohiko Uchida; Ryohei Ohtani; Satoshi Kuwabara
Journal:  Neurol Clin Pract       Date:  2021-08

7.  Cerebral Venous Thrombosis due to Cryptococcus in a Multiple Sclerosis Patient on Fingolimod.

Authors:  Joel A Kammeyer; Nicole M Lehmann
Journal:  Case Rep Neurol       Date:  2022-06-24

8.  Case Report: Fingolimod and Cryptococcosis: Collision of Immunomodulation with Infectious Disease.

Authors:  Rohini D Samudralwar; Andrej Spec; Anne H Cross
Journal:  Int J MS Care       Date:  2019 Nov-Dec

Review 9.  Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alberto Gajofatto; Marco Turatti; Salvatore Monaco; Maria Donata Benedetti
Journal:  Drug Healthc Patient Saf       Date:  2015-12-11

10.  Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study.

Authors:  Rozita Doosti; Abdorreza Naser Moghadasi; Amir Reza Azimi; Shahrokh Karbalai Saleh; Masoud Etemadifar; Vahid Shaygannejad; Fereshteh Ashtari; Mohammad Hossein Harirchian; Seyed Bahaadin Siroos; Hormoz Ayramloo; Nastaran Majdinasab; Seyyed Mohammad Masood Hojjati; Nabiollah Asghari; Seyed Mohammad Baghbanian; Hamed Cheraghmakani; Mahmoud Abedini; Behnaz Sedighi; Negar Mohseni Abbas Abadi; Maedeh Ghasemitabar; Sara Talebianpour; Tohid Babayi Daylari; Vahid Dana; Neda Ghaleh Noie; Mohammad Ali Sahraian
Journal:  Caspian J Intern Med       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.